CCBIO Seminar – Ingeborg Tinhofer-Keilholz
Welcome to a CCBIO seminar with speaker Ingeborg Tinhofer-Keilholz, Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin. Title: Advanced animal-free preclinical models for head and neck cancer.
Speaker: Dr. Ingeborg Tinhofer-Keilholz, Ass. Prof., PhD, Head Experimental Radiation Oncology Laboratory, Dept. of Radiooncology and Radiotherapy, Charité University Hospital Berlin
Title: Advanced animal-free preclinical models for head and neck cancer.
Host: Daniela Costea
Where: Auditorium 4, BB-building
When: October 27, 2022 at 14.30-15.30
No registration necessary. Join us also for the informal pizza get-together in the hall following the talk!
Inge Tinhofer-Keilholz is in the research field of head neck squamous cell carcinoma; molecular mechanisms of resistance to radiotherapy, chemotherapy and targeted treatment; development of biomarkers for improved patient stratification and personalized treatment. She has has published 124 scientific papers, and coordinates the research activities of the Charité Comprehensive Cancer Center Working Group Head and Neck Cancer. Since 2015, she is Translational Research Representative from the EORTC HNC Group and since 2020 she is member of the ESMO Faculty (HNC Group). She serves as reviewer for several high-impact journals including Lancet Oncology, Clinical Cancer Research, Annals of Oncology, and European Journal of Cancer.
Seminar focus: To describe the generation, advantages and limitations of advanced animal-free preclinical models for head and neck cancer; To present recent achievements from preclinical model studies with respect to biomarker development and therapeutic target identification.
Abstract: Comprehensive molecular characterization of head and neck squamous cell carcinoma (HNSCC) has led to the identification of distinct molecular subgroups with fundamental differences in biological properties and clinical behavior. Despite improvements in tumor classification and increased understanding about the signaling pathways involved in neoplastic transformation and disease progression, current standard-of-care treatment for HNSCC mostly remains to be based on a stage-dependent strategy whereby all patients at the same stage receive the same treatment. Preclinical models that closely resemble molecular HNSCC subgroups that can be exploited for dissecting the biological function of genetic variants and/or altered gene expression will be highly valuable for translating molecular findings into improved clinical care. In the seminar, I will discuss existing and novel information on primary two- and three-dimensional ex vivo tumor cultures from HNSCC patients. I will review their value in elucidating the basic biology of HNSCC, the molecular mechanisms of treatment resistance and their potential for the development of novel molecularly stratified treatment.
All interested researchers, students and others are welcome! No need for registration.